Table 2.
Estimate comparisons of one dose ChAdOx1 nCoV-19 in participants with prior SARS-CoV-2 infection > 1 week post vaccination with two doses BNT162b2 in SARS-CoV-2 naïve participants > 2 weeks post vaccination in the reference group. The estimate provides the multiplication factor for how much the AU/ml is modified by switching from two doses BNT162b2 in SARS-CoV-2 naïve participants to a single ChAdOx1 nCoV-19 dose in participants with prior SARS-CoV-2 infection. Estimates around 1.0 suggest no difference. All values are adjusted for sex and age. Inf; infection, m; months, vx; vaccination, RBD; receptor binding protein, NAb; neutralizing antibodies. CI; confidence interval.
| RBD IgG |
RBD NAb |
|||||
|---|---|---|---|---|---|---|
| Estimate | 95% CI | Estimate | 95% CI | |||
| Wild type | ||||||
| Inf <11m prior vx | 1.0 | (0.7 to 1.4) | 1.1 | (0.9 to 1.3) | ||
| Inf >11m prior vx | 1.6 | (1.2 to 2.1) | 1.2 | (1.0 to 1.4) | ||
| Alpha (B.1.1.7) | ||||||
| Inf <11m prior vx | 1.1 | (0.7 to 1.5) | 1.0 | (0.7 to 1.3) | ||
| Inf >11m prior vx | 1.6 | (1.2 to 2.2) | 1.2 | (1.0 to 1.5) | ||
| Beta (B.1.351) | ||||||
| Inf <11m prior vx | 1.0 | (0.6 to 1.4) | 0.7 | (0.3 to 1.8) | ||
| Inf >11m prior vx | 1.8 | (1.2 to 2.5) | 0.9 | (0.4 to 2.2) | ||
| Gamma (P.1) | ||||||
| Inf <11m prior vx | 0.9 | (0.6 to 1.4) | 1.0 | (0.6 to 1.6) | ||
| Inf >11m prior vx | 1.6 | (1.1 to 2.2) | 1.0 | (0.5 to 1.7) | ||
| Delta (B.1.617.2) | ||||||
| Inf <11m prior vx | 0.9 | (0.6 to 1.3) | 0.9 | (0.5 to 1.1) | ||
| Inf >11m prior vx | 1.4 | (1.0 to 1.9) | 1.1 | (0.9 to 1.3) | ||